MediWound (NASDAQ:MDWD) Earns “Buy” Rating from HC Wainwright

MediWound (NASDAQ:MDWDGet Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They currently have a $28.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 75.33% from the stock’s previous close.

Separately, StockNews.com downgraded MediWound from a “hold” rating to a “sell” rating in a report on Monday, February 26th.

Get Our Latest Report on MDWD

MediWound Trading Up 0.1 %

NASDAQ MDWD opened at $15.97 on Friday. The stock’s 50 day moving average is $13.83 and its two-hundred day moving average is $10.87. The company has a market capitalization of $147.08 million, a price-to-earnings ratio of -20.74 and a beta of 0.94. MediWound has a 1-year low of $7.10 and a 1-year high of $17.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Yelin Lapidot Holdings Management Ltd. acquired a new position in shares of MediWound in the 3rd quarter worth approximately $917,000. Alyeska Investment Group L.P. acquired a new position in MediWound during the 1st quarter worth $1,998,000. Sphera Funds Management LTD. lifted its holdings in MediWound by 47.4% during the 1st quarter. Sphera Funds Management LTD. now owns 111,127 shares of the biopharmaceutical company’s stock worth $1,480,000 after buying an additional 35,714 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in MediWound by 16.0% during the 2nd quarter. Wells Fargo & Company MN now owns 112,727 shares of the biopharmaceutical company’s stock worth $1,202,000 after buying an additional 15,535 shares in the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of MediWound by 3.8% during the 2nd quarter. Renaissance Technologies LLC now owns 475,422 shares of the biopharmaceutical company’s stock valued at $875,000 after acquiring an additional 17,600 shares during the last quarter. 22.32% of the stock is owned by institutional investors and hedge funds.

MediWound Company Profile

(Get Free Report)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

See Also

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.